PubMed Health⌕ Search

Biomedical subjects

M Maeta

Publications and source records attributed to M Maeta.

At least 127 records · Page 7Linked to original sources
PubMed1985

Immunosuppressive factor from the spleen in gastric cancer patients.

The spleens of gastric cancer patients were examined to determine whether this organ releases an immunosuppressive factor. Compared to serum from peripheral blood, serum from splenic venous blood of advanced gastric cancer patients had greater suppressive activity to normal lymphocyte responses to phytohemagglutinin (PHA); it also contained significantly more immune complexes. Furthermore, the supernatant from spleen cell cultures from advanced gastric cancer patients significantly suppressed normal lymphocyte responses to PHA. This immunosuppressive activity was enhanced when the supernatant was from cultures of separated nonadherent subpopulations. These observations were not detected in patients with early gastric cancer. The blastogenic response to PHA and the percentage of T-cells among spleen cells was not affected by the cancer stage. These results suggest that the spleen of patients with advanced gastric cancer participates in the induction of serum immunosuppressive factors, possibly due to a change in splenic lymphocyte subsets.

Antigen-Antibody Complex↗
PubMed1985

Clinical effects of total-body hyperthermia combined with anticancer chemotherapy for far-advanced gastrointestinal cancer.

The authors treated 17 patients with far-advanced gastrointestinal cancer with extracorporeally induced total-body hyperthermia (TBHT) combined with anticancer chemotherapy. Although all patients' tumors were clinically resistant to prior chemotherapy with 1-(2-tetrahydrofurlyl)-5-fluorouracil or 5-fluorouracil and mitomycin C, three patients had an objective response to TBHT plus the same anticancer agents with or without cyclophosphamide. That is, a partial response was obtained in 2 of 12 patients with recurrent gastric cancer and in 1 of 5 patients with recurrent large bowel cancer. However, their survival time was not markedly prolonged. As a characteristic complication of TBHT, the authors noted reversible weakness of the muscles of the lower extremities. Two patients died due to hepatorenal syndrome; preoperatively these patients had manifested hepatic or renal dysfunction. Therefore, in patients with hepatic or renal dysfunction, the application of TBHT must be considered carefully.

Adult↗
PubMed1985

Intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors.

Four hepatocellular cancer patients and 11 metastatic liver cancer patients were treated with intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) plus 5-fluorouracil. Cis-diamminedichloroplatinum (II) (25-35 mg/m2) was given once a week, 5-fluorouracil (150-180 mg/m2) was infused daily. A partial response was obtained in 3 of 4 patients with primary cancer and in 5 of 9 evaluable metastatic cancer patients; the mean response durations were 27+ weeks in the former and 47+ weeks in the latter. However, severe bone marrow suppression occurred in 4 patients; 3 died of septicemia (2 cases) and massive intra-tracheal bleeding, respectively. This combined intra-hepato-arterial chemotherapy exerts a synergistic anticancer effect on malignant liver tumors, however, the related bone marrow suppression remains to be overcome.

Adult↗
PubMed1985

[Clinical significance of the determination of serum carbohydrate antigen 19-9 in patients with carcinoma of the stomach and colorectum].

Serum CA 19-9 levels were measured in 68 gastric cancer patients and 38 cases of colorectal cancer. In patients with stage I-III gastric cancer or Duckes A-C colorectal cancer, the CA 19-9 levels ranged from normal to 127 U/ml, whereas in more advanced cases it was very high. Classified by the mode of recurrence, the highest level of CA 19-9 was observed in liver metastasis. After removal of the main tumor, the CA 19-9 level declined rapidly, increasing with recurrence. Serum CA 19-9 determination in cases of gastric or colorectal cancer was useful to classify the stage of disease, developing a prognosis and identifying a recurrence.

Antigens, Neoplasm↗
PubMed1985

Effects of total-body hyperthermia on metastases from experimental mouse tumors.

To study the effects of total-body hyperthermia (TBH) on metastases from malignant tumors, Lewis lung carcinoma (LLC)-bearing C57BL/6 mice and mouse ascites hepatoma 134-bearing C3H/He mice were immersed in a heated water bath. Rectal temperature was maintained for 30 min at 40 degrees C or 42 degrees C. After treatment, the incidence of lung metastasis was analyzed in LLC-inoculated mice, and the presence or absence of metastasis in affiliated lymph nodes was determined in mouse ascites hepatoma 134-inoculated mice. A significant inhibition in primary tumor growth in LLC- and mouse ascites hepatoma 134-bearing mice treated with 42 degrees C TBH was noted. The incidence of lung metastasis was increased from the control level of 1.6 +/- 0.63 (SD) to 2.4 +/- 0.98 in the 42 degrees C TBH (P less than 0.01) groups but not in the 40 degrees C TBH group. Metastasis to affiliated lymph nodes was similar for the controls and the 40 degrees C and 42 degrees C TBH groups. The increase in lung metastasis in LLC-treated mice subjected to 42 degrees C TBH could be prevented by the combined use of anticancer drugs such as cis-diamminedichloroplatinum(II) (1.0, 3.0 mg/kg) or mitomycin C (0.3, 1.0 mg/kg). Furthermore, the combined use of 42 degrees C TBH and anticancer drugs showed the inhibition of primary tumor growth to a greater degree than did 42 degrees C TBH alone or anticancer drugs alone. Since 42 degrees C TBH may induce tumor metastasis, especially hematogenous metastasis, it seems advisable to use anticancer drugs in combination with clinical thermal applications.

Animals↗
PubMed1985

[Total-body hyperthermia and combined anticancer chemotherapy].

The present status of extracorporeally induced total-body hyperthermia (TBHT) for far-advanced cancer was presented from data collected from Japanese patients given this treatment. TBHT was most effective in lung cancer. In analyzing the anticancer effects of TBHT according to cancer site, the highest efficacy was observed in patients with their main cancer in the lung or liver, irrespective of whether tumorigenesis was primary or secondary. The anticancer effects were more enhanced when TBHT was combined with dosage of cis-DDP. What is important in combined chemotherapy is to determine what agent(s) should be applied and when. The most useful method for examining the thermosensitivity and thermochemosensitivity of agents for drug selection was the human tumor stem cell assay using individual cancer cells. Further, the usefulness of angiotensin II-induced hypertensive chemotherapy during TBHT in augmenting selective drug delivery to tumors was stressed.

Angiotensin II↗
PubMed1984

Circulating immune complexes in gastric cancer patients and their effect on lymphocyte mitogenesis (the first report).

Immune complexes (IC) were measured in 66 gastric cancer patients, using the 3.5 percent polyethylene glycol (PEG) precipitation method. Preoperatively, the IC values in patients with advanced gastric cancer (stages III and IV) were significantly higher than in normal subjects (p less than 0.01). In the presence of 3.5 percent PEG-precipitated IC from sera of gastric cancer patients, the mitogen responses of normal peripheral blood lymphocytes was inhibited; the PHA response revealed a significant negative correlation with the concentration of IC (p less than 0.01). Our data suggest that IC may be a major serum factor exerting immunosuppressive effect in cancer hosts.

Antigen-Antibody Complex↗
PubMed1984

Effect of extracorporeally induced total body hyperthermia for cancer on cardiovascular function.

Total body hyperthermia (TBHT) was induced in patients with terminal cancer, using a femoral arterio-venous shunt as an extracorporeal circuit incorporating a heat exchanger. A total of 31 systemic hyperthermic treatments lasting 3 to 4 hours at 41.5 degrees C to 42 degrees C (rectal temperature) were performed on 11 patients; chemotherapy had previously been unsuccessful in all of these cases. The effect of TBHT on cardiovascular function was explored in these patients. The heart rate and cardiac output were always markedly increased during hyperthermia, however, the peripheral arterial, central venous, pulmonary arterial and pulmonary wedge pressures were little affected and no progressive metabolic acidosis occurred. TBHT was generally well tolerated and there was no instance in which this treatment had to be terminated because of severe cardiovascular failure during hyperthermia.

Adult↗
PubMed1984

[Combination chemotherapy with neocarzinostatin(NCS), HCFU and picibanil(NHO therapy) for advanced carcinoma of the digestive system--a comparative study with NF, and NFO therapy].

We have previously reported the clinical effects of NF therapy (NCS + 5-FU) and NFO therapy (NCS + 5-FU + Picibanil) on patients with advanced carcinoma of the digestive organs. In the present study, (NHO therapy (NCS + HCFU + Picibanil) performed in 41 patients and 30 patients were evaluated for its clinical effects. In comparison with NHO, NF and NFO, partial regression (tumor regression exceeding 50%) was noted in 5 of 30 patients (16.7%) on NHO, which was superior to 7.4% on NF, but slightly inferior to 18.8% on NFO. However, six and twelve month survival rate and 50% survival month on NHO therapy were 31.6%, 10.5% and 4.6 months, respectively and they were superior to those of NF and NFO therapy. Though the incidence of the adverse effects by NHO was almost identical with that of NFO and not more frequent than that of NF therapy. Urinary frequency, hot sensation and urgency due to HCFU administration were observed approximately in 10% on NFO therapy. In the three modalities the advantageous clinical effects on patients with hepatic carcinoma irrespective of primary or metastatic were observed.

Adult↗
PubMed1984

[Serum levels of mitomycin C following a high-dose continuous hyperthermic peritoneal perfusion].

Valid therapeutic means have not been established for treatment of disseminated peritoneal metastasis of carcinoma. Continuous hyperthermic peritoneal perfusion (CHPP) with high-dose of mitomycin-C (MMC) was applied to 26 patients with peritoneal metastasis from gastric, rectal or ovarian cancers. Levels of MMC in the sera and in the perfusate were measured. The results obtained were: 1. Approximately a half of the dose of MMC added into the perfusion fluid was recovered. 2. When perfused with 100 mg of MMC, the maximum serum concentration of MMC was equivalent to 1/3 of the maximum serum level when injected with 10 mg of MMC intravenously. Therefore, MMC which could not be detected in CHPP seemed to be retained in the abdominal cavity. 3. Bone marrow inhibition caused by CHPP was observed in only 2 of 26 patients. 4. The total dose of 300 mg of MMC, consisting of the maximum dose of 100 mg each, is acceptable in CHPP without any severe side effect. 5. CHPP exerts antitumor effects when utilizing hyperthermia and a high-dose of MMC on the disseminated peritoneal foci of carcinoma.

Female↗
PubMed1984

Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug.

To study the feasibility of combined hyperthermic and anticancer drug treatment for peritoneal cancer, we devised a continuous hyperthermic peritoneal perfusion system in combination with mitomycin C. The model uses i.p.-transplantable rat ascites hepatoma 100B cells. Hyperthermic peritoneal perfusion alone or combined with mitomycin C was performed after i.p. inoculation of the tumor cells into rats. In rats treated with combined peritoneal perfusion (41.5 degrees) and mitomycin C, the mean survival times were significantly prolonged as compared to those of rats treated with peritoneal perfusion at 41.5 degrees alone. Our results suggest that combined hyperthermic peritoneal perfusion and mitomycin C treatment may represent a therapeutic and prophylactic treatment for peritoneal metastasis after gastric cancer surgery in humans.

Animals↗
PubMed1984

[Intra-hepato-arterial administration of cis-diammine-dichloroplatinum II (CDDP) for primary or metastatic hepatic cancer].

To study the effectiveness of CDDP for hepatic cancer, intra-hepato-arterial administration of CDDP (0.8-1.0 mg/kg/week) combined with 5-FU (250 mg/body/day) was performed for 10 patients with primary or metastatic hepatic cancer. As the results, partial response was obtained in 6 of 8 evaluable patients. However, the adverse effect was very high rate; leucopenia, thrombocytopenia and vomiting (nausea) were observed in 9, 6 and 6 of 10 patients respectively. The dose limiting factor of CDDP was not a nephrotoxicity but a bone marrow depression in this series. Though a noticeable antitumor effect of this modality was obtained, some improvements should be applied to it to decrease the adverse effect.

Adult↗
PubMed1983

The effects of total-body hyperthermia combined with anticancer drugs on immunity in advanced cancer patients.

As total-body hyperthermia (TBHT) therapy may lead to a reduction in the immune response of cancer patients because of the immediate effect of heat on lymphocytes, the authors studied the immunity of advanced cancer patients receiving combined TBHT and anticancer chemotherapy. A decrease was found in their lymphocyte blastogenesis, skin reactions to PPD and PHA, lymphocyte rosette formation, IgG, and C3c component. These parameters returned to their pretreatment levels at 1 week after completion of TBHT therapy. This result indicates that there is no necessity for giving special consideration to a reduction of cell-mediated immunity in TBHT therapy.

Adult↗
PubMed1983

Effects of in vitro hyperthermia on murine and human lymphocytes.

The effect of in vitro hyperthermia on the immune response of murine and human lymphocytes was investigated. Viability, blastogenesis and cytotoxic activity of murine lymphocytes were reduced at 39 and 42 degrees C hyperthermia. In human lymphocytes, rosette formation inhibition depended on heating-time and temperature. PHA-induced lymphocyte blastogenesis was markedly inhibited at 42 degrees C, irrespective of the duration of exposure and of the origin of the cells, although it was enhanced in some patients at 39 degrees C. Therefore, the possibility of hyperthermia-induced inhibition of the host immune response must be considered in clinical trials of total-body hyperthermia for cancer.

Animals↗